GenSight Biologics S.A. (EPA:SIGHT)
 0.1264
 -0.0130 (-9.33%)
  Nov 3, 2025, 5:35 PM CET
GenSight Biologics Employees
GenSight Biologics had 16 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees 
 16
Change (1Y) 
 n/a
Growth (1Y) 
 n/a
Revenue / Employee 
 €72,692
Profits / Employee 
 €1,163,077
Market Cap 
22.00M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 16 | 0 | - | 
| Dec 31, 2023 | 16 | -29 | -64.44% | 
| Dec 31, 2022 | 45 | 7 | 18.42% | 
| Dec 31, 2021 | 38 | 13 | 52.00% | 
| Dec 31, 2020 | 25 | 0 | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| EssilorLuxottica Société anonyme | 153,498 | 
| emeis Société anonyme | 83,494 | 
| Sanofi | 82,878 | 
| Eurofins Scientific SE | 62,696 | 
| Clariane SE | 61,798 | 
| bioMérieux | 14,754 | 
| Sartorius Stedim Biotech | 9,901 | 
| Virbac | 6,365 | 
GenSight Biologics News
- 5 days ago - GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US - Business Wire
 - 27 days ago - GenSight Biologics Reports Cash Position as of September 30, 2025 - Business Wire
 - 5 weeks ago - GenSight Biologics Reports Interim Financial Results for the First Half of 2025 - Business Wire
 - 2 months ago - GenSight Biologics Postpones Release of 2025 Half-Year Financial Results - Business Wire
 - 3 months ago - GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy - Business Wire
 - 4 months ago - GenSight Biologics Reports Cash Position as of June 30, 2025 - Business Wire
 - 5 months ago - GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France - Business Wire
 - 6 months ago - GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025 - Business Wire